Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EZH2 | Q15910 | 8/20 | 0.70 |
| ▸ | EZH1 | Q92800 | 4/20 | 0.70 |
| ▸ | HDAC6 | Q9UBN7 | 11/20 | 0.67 |
| ▸ | EED | O75530 | 2/20 | 0.60 |
| ▸ | SUZ12 | Q15022 | 2/20 | 0.60 |
| ▸ | HDAC1 | Q13547 | 9/20 | 0.58 |
| ▸ | RBBP4 | Q09028 | 1/20 | 0.54 |
| ▸ | RBBP7 | Q16576 | 1/20 | 0.54 |
| ▸ | AEBP2 | Q6ZN18 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21285011 | 0.93 | EZH2 (0.71) | EZH2EZH1HDAC6EEDSUZ12 | |
| SCHEMBL22604802 | 0.89 | EZH2 (0.78) | EZH2EZH1HDAC6EEDSUZ12 | |
| SCHEMBL30122920 | 0.89 | EZH2 (0.79) | EZH2EZH1HDAC6EEDSUZ12 | |
| SCHEMBL22582153 | 0.89 | EZH2 (0.79) | EZH2EZH1HDAC6EEDSUZ12 | |
| SCHEMBL21271633 | 0.88 | EZH2 (0.73) | EZH2EZH1HDAC6EEDSUZ12 | |
| SCHEMBL21271725 | 0.88 | EZH2 (0.79) | EZH2EZH1HDAC6EEDSUZ12 | |
| SCHEMBL30122966 | 0.88 | EZH2 (0.73) | EZH2EZH1HDAC6EEDSUZ12 | |
| SCHEMBL21271632 | 0.88 | EZH2 (0.73) | EZH2EZH1HDAC6EEDSUZ12 | |
| SCHEMBL30122968 | 0.88 | EZH2 (0.79) | EZH2EZH1HDAC6EEDSUZ12 | |
| SCHEMBL22604558 | 0.86 | EZH2 (0.64) | EZH2EZH1HDAC6EEDSUZ12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230114294-A1 | COMPOSITIONS AND METHODS FOR TREATING EZH2-MEDIATED CANCER | ICAHN SCHOOL MED MOUNT SINAI (US) | 2023-04-13 | — | — | US | disclosed |
| US-20200338070-A1 | COMPOSITIONS AND METHODS FOR TREATING EZH2-MEDIATED CANCER | ICAHN SCHOOL MED MOUNT SINAI (US) | 2020-10-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200338070-A1 | COMPOSITIONS AND METHODS FOR TREATING EZH2-MEDIATED CANCER | EZH2, EZH1, EED | EZH2 1/4885EZH1 2/4885HDAC6 138/4885 |
| US-20230114294-A1 | COMPOSITIONS AND METHODS FOR TREATING EZH2-MEDIATED CANCER | EZH2, EZH1, EED | EZH2 1/4885EZH1 2/4885HDAC6 138/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.